Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Santiago Olszevicki
Observed names:
Olszevicki, Santiago,
S. Olszevicki
Institution:
Instituto Cardiovascular de Buenos Aires
Observed institutions:
Consejo Nacional de Investigaciones Científicas y Técnicas,
Universidad de Buenos Aires,
Ministerio de Salud,
Ministerio de Salud - Provincia de Buenos Aires,
Instituto Cardiovascular de Buenos Aires
ORCID:
0000-0002-4697-4113
Observed ORCID:
0000-0002-4697-4113
OpenAlex ID:
A5076179110
Real-world effectiveness of RSVpreF vaccination during pregnancy against RSV-associated lower respiratory tract disease leading to hospitalisation in infants during the 2024 RSV season in Argentina (BERNI study): a multicentre, retrospective, test-negative, case–control study
2025
·
Gonzalo Pérez Marc
, Carla Vizzotti
, et al.
·
The Lancet Infectious Diseases
·
119
SARS-CoV-2 Infection Boosts MX1 Antiviral Effector in COVID-19 Patients
2020
·
Juan Bizzotto
, Pablo Sanchis
, et al.
·
iScience
·
105
PDF
Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina
2021
·
Soledad González
, Santiago Olszevicki
, et al.
·
EClinicalMedicine
·
83
PDF
Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study
2022
·
Juan Manuel Castelli
, Analia Rearte
, et al.
·
BMJ
·
41
PDF
Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
2022
·
Soledad González
, Santiago Olszevicki
, et al.
·
The Lancet Regional Health - Americas
·
36
PDF
Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
2023
·
Soledad González
, Santiago Olszevicki
, et al.
·
The Lancet Regional Health - Americas
·
13
Predicting prostate cancer progression with a Multi-lncRNA expression-based risk score and nomogram integrating ISUP grading
2024
·
Sabrina Ledesma-Bazan
, Florencia Cascardo
, et al.
·
Non-coding RNA Research
·
6
Prognostic impact of myocardial flow reserve assessed by cadmium–zinc–telluride single-photon emission computed tomography
2026
·
María Victoria Carvelli
, Osvaldo H. Masoli
, et al.
·
Journal of Nuclear Cardiology
·
3
Prognostic Impact of Myocardial Flow Reserve Evaluated By CZT SPECT
2025
·
Maria Victoria Carvelli
, Alejandro H. Meretta
, et al.
·
Journal of Nuclear Cardiology
More evidence needed for maternal RSVpreF protection to age 6 months – Authors' reply
2025
·
Analia Rearte
, Gonzalo Peréz Marc
, et al.
·
The Lancet Infectious Diseases
PDF
Efectividad de refuerzos homólogos y heterólogos luego de esquemas primarios con Sputnik V, Astra-Zeneca y Sinopharm durante el período omicron en adultos mayores de 50 años en la provincia de Buenos Aires
2023
·
González, Soledad
, Olszevicki, Santiago
, et al.
·
SALUD publica: revista del Ministerio de Salud de la Provincia de Buenos Aires
PDF
Abstract 710: Androgen-deprivation therapy boosts MX1 expression, a silent effector against COVID-19
2021
·
Juan Antonio Bizzotto
, Pablo Sanchis
, et al.
·
Cancer Research
Unveiling the Silent Antiviral Effectors Fighting Against COVID-19
2020
·
M. Abbate
, J. Bizzotto
, et al.
·
SSRN Electronic Journal
Show more works
View as search
Works count:
13
Citation count:
406
H-index:
6
I10-index:
6
Year
Topic
Type